Kala Pharmaceuticals Financials
KALA Stock | USD 6.55 0.12 1.87% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 6.47 | 6.3348 |
|
|
The financial analysis of Kala Pharmaceuticals is a critical element in measuring its lifeblood. Investors should not minimize Kala Pharmaceuticals' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Kala | Select Account or Indicator |
Understanding current and past Kala Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Kala Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Kala Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Kala Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kala Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kala Pharmaceuticals' management manipulating its earnings.
Kala Pharmaceuticals Stock Summary
Kala Pharmaceuticals competes with Lifecore Biomedical, Shuttle Pharmaceuticals, Journey Medical, Akanda Corp, and Organogenesis Holdings. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts. Kala Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 192 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US4831191030 |
CUSIP | 483119103 483119202 |
Location | Massachusetts; U.S.A |
Business Address | 1167 Massachusetts Avenue, |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.kalarx.com |
Phone | 781 996 5252 |
Currency | USD - US Dollar |
Kala Pharmaceuticals Key Financial Ratios
Return On Equity | -2.48 | ||||
Price To Sales | 1.16 X | ||||
Gross Profit | 1.33 M | ||||
EBITDA | (36.08 M) | ||||
Net Income | (42.2 M) |
Kala Pharmaceuticals Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 154.3M | 221.6M | 139.4M | 86.8M | 55.9M | 53.2M | |
Net Tangible Assets | 29.7M | 100.0M | 16.8M | 19.0M | 21.8M | 21.4M | |
Retained Earnings | (295.5M) | (399.8M) | (542.4M) | (587.2M) | (629.4M) | (597.9M) | |
Accounts Payable | 2.5M | 1.7M | 2.8M | 2.3M | 919K | 873.1K | |
Cash | 85.4M | 77.3M | 92.1M | 70.5M | 50.9M | 79.6M | |
Other Assets | 16.4M | 47.1M | 11.0M | 462K | 531.3K | 504.7K | |
Long Term Debt | 71.2M | 72.2M | 78.9M | 37.9M | 34.2M | 43.8M | |
Net Receivables | 13.1M | 9.9M | 17.5M | 6.5M | 236K | 224.2K | |
Other Current Assets | 1.6M | 2.8M | 6.1M | 9.0M | 1.7M | 2.5M | |
Total Liab | 124.6M | 121.6M | 122.6M | 67.8M | 48.4M | 91.9M | |
Total Current Assets | 105.5M | 171.4M | 124.4M | 85.9M | 52.9M | 98.6M | |
Short Term Debt | 1.3M | 3.1M | 1.4M | 5.0M | 668K | 634.6K | |
Common Stock | 36K | 59K | 66K | 2K | 3K | 2.9K | |
Other Current Liab | 20.9M | 17.4M | 33.2M | 14.1M | 5.7M | 5.4M | |
Net Debt | 15.7M | 23.7M | (11.9M) | (27.5M) | (14.6M) | (15.3M) | |
Long Term Debt Total | 12.0M | 70.2M | 71.2M | 72.2M | 83.1M | 44.5M | |
Capital Surpluse | 224.0M | 306.1M | 325.1M | 499.7M | 574.7M | 603.4M | |
Inventory | 4.6M | 5.2M | 8.6M | 7.7M | 8.8M | 5.6M | |
Net Invested Capital | 100.9M | 172.2M | 95.7M | 61.9M | 41.7M | 39.6M | |
Net Working Capital | 80.7M | 149.2M | 86.9M | 60.3M | 44.5M | 78.0M |
Kala Pharmaceuticals Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 8.5M | 8.6M | 8.4M | 7.3M | 5.8M | 4.9M | |
Gross Profit | 4.1M | 3.2M | 7.1M | 1.3M | (303K) | (287.9K) | |
Operating Income | (88.2M) | (96.2M) | (109.4M) | (81.4M) | (39.2M) | (41.1M) | |
Ebit | (88.2M) | (95.7M) | (134.2M) | (37.6M) | (36.4M) | (38.2M) | |
Research Development | 27.3M | 18.4M | 11.5M | 17.7M | 18.6M | 21.9M | |
Cost Of Revenue | 2.0M | 3.2M | 4.1M | 2.6M | 303K | 287.9K | |
Income Before Tax | (94.3M) | (104.3M) | (142.6M) | (44.8M) | (42.2M) | (44.3M) | |
Net Income | (102.0M) | (112.0M) | (152.3M) | (223K) | (42.2M) | (44.3M) | |
Income Tax Expense | 7.6M | 7.7M | 9.7M | (44.6M) | (40.1M) | (38.1M) | |
Interest Income | 2.4M | 493K | 104K | 664K | 2.5M | 2.6M | |
Ebitda | (85.9M) | (92.9M) | (132.0M) | (36.7M) | (36.1M) | (37.9M) | |
Net Interest Income | (6.1M) | (8.1M) | (8.3M) | (6.6M) | (3.5M) | (3.6M) |
Kala Pharmaceuticals Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (85.1M) | (8.3M) | 5.1M | (24.1M) | (19.9M) | (18.9M) | |
Net Borrowings | (30K) | (32K) | 2.0M | (40.0M) | (36.0M) | (34.2M) | |
Depreciation | 843K | 912K | 975K | 537K | 303K | 287.9K | |
Capital Expenditures | 1.3M | 1.9M | 886K | 313K | 610K | 855.1K | |
Net Income | (94.3M) | (104.3M) | (142.6M) | (44.8M) | (42.2M) | (44.3M) | |
End Period Cash Flow | 98.0M | 89.8M | 94.9M | 70.7M | 50.9M | 84.1M | |
Change To Netincome | 10.0M | 13.3M | 42.5M | (36.5M) | (42.0M) | (39.9M) | |
Change To Inventory | (4.3M) | (2.4M) | (6.3M) | 1.7M | 7.5M | 7.9M | |
Free Cash Flow | (94.1M) | (92.6M) | (109.1M) | (79.2M) | (28.5M) | (30.0M) | |
Other Non Cash Items | 2.7M | 3.0M | 22.5M | (42.1M) | (2.4M) | (2.5M) |
Kala Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kala Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kala Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kala Pharmaceuticals competition to find correlations between indicators driving Kala Pharmaceuticals's intrinsic value. More Info.Kala Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Kala Pharmaceuticals' Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kala Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Kala Pharmaceuticals Systematic Risk
Kala Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kala Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Kala Pharmaceuticals correlated with the market. If Beta is less than 0 Kala Pharmaceuticals generally moves in the opposite direction as compared to the market. If Kala Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kala Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kala Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Kala Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Kala Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kala Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Kala Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Kala Pharmaceuticals November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Kala Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kala Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kala Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Kala Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kala Pharmaceuticals's daily price indicators and compare them against related drivers.
Downside Deviation | 2.21 | |||
Information Ratio | 9.0E-4 | |||
Maximum Drawdown | 15.25 | |||
Value At Risk | (3.85) | |||
Potential Upside | 6.54 |
Complementary Tools for Kala Stock analysis
When running Kala Pharmaceuticals' price analysis, check to measure Kala Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kala Pharmaceuticals is operating at the current time. Most of Kala Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kala Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kala Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kala Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Transaction History View history of all your transactions and understand their impact on performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |